Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sherene Loi

Showing results (121-130 of 325) with videos related to

Pageof 33
Sort By:
Plos One|January 10, 2013
PIK3CA genotype and a PIK3CA mutation-related gene signature and response to everolimus and letrozole in estrogen receptor positive breast cancerSherene Loi, Stefan Michiels, Jose Baselga, et al.
The Lancet. Oncology|June 2, 2012
A common language in neoadjuvant breast cancer clinical trials: proposals for standard definitions and endpointsDebora Fumagalli, Philippe L Bedard, Zeina Nahleh, et al.
Plos One|April 24, 2019
Correction: PIK3CA Genotype and a PIK3CA Mutation-Related Gene Signature and Response to Everolimus and Letrozole in Estrogen Receptor Positive Breast CancerSherene Loi, Stefan Michiels, Jose Baselga, et al.
The New England Journal of Medicine|June 2, 2015
Palbociclib in Hormone-Receptor-Positive Advanced Breast CancerNicholas C Turner, Jungsil Ro, Fabrice André, et al.
Science Advances|February 23, 2022
PTPN2 elicits cell autonomous and non-cell autonomous effects on antitumor immunity in triple-negative breast cancerPei Kee Goh, Florian Wiede, Mara N Zeissig, et al.
Journal of the National Cancer Institute|May 28, 2021
Assessment of Ovarian Function in Phase III (Neo)Adjuvant Breast Cancer Clinical Trials: A Systematic EvaluationWanyuan Cui, Prudence A Francis, Sherene Loi, et al.
Cancer Discovery|September 13, 2018
The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 TrialBen O'Leary, Rosalind J Cutts, Yuan Liu, et al.
Asia-Pacific Journal of Clinical Oncology|December 15, 2021
Palbociclib plus letrozole as treatment for postmenopausal women with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer for whom letrozole therapy is deemed appropriate: An expanded access study in Australia and IndiaSherene Loi, Christos S Karapetis, Nicole McCarthy, et al.
JACC. Cardiooncology|August 16, 2021
Exercise Attenuates Cardiotoxicity of Anthracycline Chemotherapy Measured by Global Longitudinal StrainBenedict T Costello, Timothy J Roberts, Erin J Howden, et al.
Journal of the National Cancer Institute|March 31, 2021
Tumor Cellularity and Infiltrating Lymphocytes as a Survival Surrogate in HER2-Positive Breast CancerNuria Chic, Stephen J Luen, Paolo Nuciforo, et al.
Pageof 33

Showing results (121-130 of 325) with videos related to

Sort By:
Pageof 33
Plos One|January 10, 2013
PIK3CA genotype and a PIK3CA mutation-related gene signature and response to everolimus and letrozole in estrogen receptor positive breast cancerSherene Loi, Stefan Michiels, Jose Baselga, et al.
The Lancet. Oncology|June 2, 2012
A common language in neoadjuvant breast cancer clinical trials: proposals for standard definitions and endpointsDebora Fumagalli, Philippe L Bedard, Zeina Nahleh, et al.
Plos One|April 24, 2019
Correction: PIK3CA Genotype and a PIK3CA Mutation-Related Gene Signature and Response to Everolimus and Letrozole in Estrogen Receptor Positive Breast CancerSherene Loi, Stefan Michiels, Jose Baselga, et al.
The New England Journal of Medicine|June 2, 2015
Palbociclib in Hormone-Receptor-Positive Advanced Breast CancerNicholas C Turner, Jungsil Ro, Fabrice André, et al.
Science Advances|February 23, 2022
PTPN2 elicits cell autonomous and non-cell autonomous effects on antitumor immunity in triple-negative breast cancerPei Kee Goh, Florian Wiede, Mara N Zeissig, et al.
Journal of the National Cancer Institute|May 28, 2021
Assessment of Ovarian Function in Phase III (Neo)Adjuvant Breast Cancer Clinical Trials: A Systematic EvaluationWanyuan Cui, Prudence A Francis, Sherene Loi, et al.
Cancer Discovery|September 13, 2018
The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 TrialBen O'Leary, Rosalind J Cutts, Yuan Liu, et al.
Asia-Pacific Journal of Clinical Oncology|December 15, 2021
Palbociclib plus letrozole as treatment for postmenopausal women with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer for whom letrozole therapy is deemed appropriate: An expanded access study in Australia and IndiaSherene Loi, Christos S Karapetis, Nicole McCarthy, et al.
JACC. Cardiooncology|August 16, 2021
Exercise Attenuates Cardiotoxicity of Anthracycline Chemotherapy Measured by Global Longitudinal StrainBenedict T Costello, Timothy J Roberts, Erin J Howden, et al.
Journal of the National Cancer Institute|March 31, 2021
Tumor Cellularity and Infiltrating Lymphocytes as a Survival Surrogate in HER2-Positive Breast CancerNuria Chic, Stephen J Luen, Paolo Nuciforo, et al.
Pageof 33